BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

As rescanning documents *will not* correct images, please do not report the images to the Image Problem Mailbox.

Listing of Claims:

Claims 1 - 31 are cancelled

32. (new) A transdermal therapeutic system comprising:

a.) an impermeable covering layer comprised of one selected from the group consisting of:

polyester, polypropylene, polyurethane, and polyethylene;

b.) a matrix layer comprised of one selected from the group consisting of:

polyacrylate, silicone, polyisobutylene, natural rubber, a synthetic rubber homopolymer, a synthetic rubber copolymer, and a synthetic rubber block polymer;

wherein said matrix layer further is made as one selected from the group consisting of:

i.) self-adhesive; and

ii.) contact adhesive-coated;

c.) at least one first active ingredient, contained in said matrix layer, said at least one first active ingredient being selected from the group consisting of:
candesartan, a pharmaceutically acceptable ester thereof,
and a pharmaceutically acceptable salt thereof; and

d.) a detachable protective layer comprised of one selected from the group consisting of:

polyester, polypropylene, polysiloxane, polyacrylate, ethylene/ vinyl acetate, polyurethane, polyisobutene, silicone-coated paper, and polyethylene-coated paper.

33. (new) The transdermal therapeutic system according to claim 32, wherein said pharmaceutically acceptable salt of candesartan is selected from the group consisting of:
the potassium salt, the sodium salt, the lithium salt, and the ammonium salt.

34. (new) The transdermal therapeutic system according to claim 32, wherein said matrix layer further comprises at least one selected from the group consisting of: at least one second active ingredient different from said first active ingredient, at least one permeation promoter, at least one amino acid, at least one calcium channel blocker, and at least one diuretic.

35. (new) The transdermal therapeutic system according to claim 34, wherein said permeation promoter is selected from the group consisting of: monohydric aliphatic alcohols with up to 8 carbon atoms; monohydric cycloaliphatic alcohols with up to 8 carbon atoms; monohydric aliphatic-aromatic alcohols with up to 8 carbon atoms; polyhydric aliphatic alcohols with up to 8 carbon atoms; polyhydric cycloaliphatic alcohols with up to 8 carbon atoms; polyhydric aliphatic-aromatic alcohols with up to 8 carbon atoms; polyethylene glycol; alcohol/water mixtures; saturated fatty alcohols with 8 - 18 carbon atoms; unsaturated fatty alcohols with 8 - 18 carbon atoms; terpenes; mixtures of a terpene and ethanol; mixtures of a terpene and propylene glycol; mixtures of a terpene, ethanol, and propylene glycol; tea tree oil; saturated cyclic ketones; unsaturated cyclic ketones; alkylmethyl sulfoxides; saturated fatty acids with 8 - 18 carbon atoms; esters of saturated fatty acids with 8 - 18 carbon atoms; salts of saturated fatty acids with 8 - 18 carbon atoms; unsaturated fatty acids with 8 - 18 carbon atoms; esters of unsaturated fatty acids with 8 - 18 carbon atoms; salts of unsaturated fatty acids with 8 - 18 carbon atoms; natural vitamin E; synthetic vitamin E; derivatives of natural vitamin E; derivatives of synthetic vitamin E; sorbitan fatty acid esters; ethoxylated sorbitan fatty acid esters; Azone (laurocapram); Azone/alcohol mixtures; urea; 1-alkylpyrrolidone; block copolymers of polyethylene glycol and dimethylsiloxane with cationic groups at one end; folate-polyethylene glycol liposome; folate-polyethylene glycol proliposome; polyoxyethylene 10 stearyl ether; mixtures of polyoxyethylene 10 stearyl ether and glyceryl dilaurate; dodecyl 2-(N,N-dimethylamino)-propanoltetradecanoate esters with more than 8 carbon atoms; dodecyl 2-(N,N-

dimethylamino)propionateN-acetylprolinate esters with more than 8 carbon atoms; nonionic surfactants, esters of polyoxyethylene; ethosome (phospholipid vesicle); dimethyl(arylimino)sulfurane; mixture of an oleic acid analog and propylene glycol; mixtures of padimate O, octyl salicylate, octyl methoxycinnamate and laurocapram; and mixtures of the foregoing.

36. (new) A transdermal therapeutic system comprising:

a.) an impermeable covering layer comprised of one selected from the group consisting of:
polyester, polypropylene, polyurethane, and polyethylene;

b.) a reservoir layer comprising one selected from the group consisting of:

i.) a material defining a space for containing at least a first active ingredient; and

ii.) a material for releasably absorbing at least a first active ingredient;

c.) at least one first active ingredient, contained in said reservoir layer, said at least one first active ingredient being selected from the group consisting of:
candesartan, a pharmaceutically acceptable ester thereof, and a pharmaceutically acceptable salt thereof;

d.) a semipermeable membrane comprised of an inert polymer selected from the group consisting of:
polypropylene, polyvinyl acetate, polyamide, ethylene/vinyl acetate copolymers, and silicone; and

e.) a detachable protective layer comprised of one selected from the group consisting of:
polyester, polypropylene, polysiloxane, polyacrylate, ethylene/ vinyl acetate, polyurethane, polyisobutene, silicone-coated paper, and polyethylene-coated paper.

37. (new) The transdermal therapeutic system according to claim 36, further comprising:

e.) a contact adhesive layer

38. (new) The transdermal therapeutic system according to claim 36, wherein said pharmaceutically acceptable salt of candesartan is selected from the group consisting of:

the potassium salt, the sodium salt, the lithium salt, and the ammonium salt.

39. (new) The transdermal therapeutic system according to claim 36, wherein said matrix layer further comprises at least one selected from the group consisting of:

at least one second active ingredient different from said first active ingredient, at least one permeation promoter, at least one amino acid, at least one calcium channel blocker, and at least one diuretic.

40. (new) The transdermal therapeutic system according to claim 34, wherein said permeation promoter is selected from the group consisting of:

monohydric aliphatic alcohols with up to 8 carbon atoms; monohydric cycloaliphatic alcohols with up to 8 carbon atoms; monohydric aliphatic-aromatic alcohols with up to 8 carbon atoms; polyhydric aliphatic alcohols with up to 8 carbon atoms; polyhydric cycloaliphatic alcohols with up to 8 carbon atoms; polyhydric aliphatic-aromatic alcohols with up to 8 carbon atoms; polyethylene glycol; alcohol/water mixtures; saturated fatty alcohols with 8 - 18 carbon atoms; unsaturated fatty alcohols with 8 - 18 carbon atoms; terpenes; mixtures of a terpene and ethanol; mixtures of a terpene and propylene glycol; mixtures of a terpene, ethanol, and propylene glycol; tea tree oil; saturated cyclic ketones; unsaturated cyclic ketones; alkylmethyl sulfoxides; saturated fatty acids with 8 - 18 carbon atoms; esters of saturated fatty acids with 8 - 18 carbon atoms; salts of saturated fatty acids with 8 - 18 carbon atoms; unsaturated fatty acids with 8 - 18 carbon atoms; esters of unsaturated fatty acids with 8 - 18 carbon atoms; salts of unsaturated fatty acids with 8 - 18 carbon atoms; natural vitamin E; synthetic

vitamin E; derivatives of natural vitamin E; derivatives of synthetic vitamin E; sorbitan fatty acid esters; ethoxylated sorbitan fatty acid esters; Azone (laurocapram); Azone/alcohol mixtures; urea; 1- alkylpyrrolidone; block copolymers of polyethylene glycol and dimethylsiloxane with cationic groups at one end; folate-polyethylene glycol liposome; folate-polyethylene glycol proliposome; polyoxyethylene 10 stearyl ether; mixtures of polyoxyethylene 10 stearyl ether and glyceryl dilaurate; dodecyl 2-(N,N-dimethylamino)-propanoltetradecanoate esters with more than 8 carbon atoms; dodecyl 2-(N,N-dimethylamino)propionateN-acetylprolinate esters with more than 8 carbon atoms; nonionic surfactants, esters of polyoxyethylene; ethosome (phospholipid vesicle); dimethyl(arylimino)sulfurane; mixture of an oleic acid analog and propylene glycol; mixtures of padimate O, octyl salicylate, octyl methoxycinnamate and laurocapram; and mixtures of the foregoing.

41. (new) The transdermal therapeutic system according to claim 37, wherein said contact adhesive layer comprises a pressure-sensitive adhesive comprising a material selected from the group consisting of:
polyurethane, polyisobutylene, polyvinyl ether, silicone, and acrylate.

42. (new) The transdermal therapeutic system according to claim 41, wherein when said contact adhesive layer comprises silicone, it is further comprised by:

i.) an adhesive polymer; and

ii.) a tack-increasing resin.

43. (new) The transdermal therapeutic system according to claim 41, wherein said pressure-sensitive adhesive is selected from the group consisting of:
polysiloxane, trimethylated silicon dioxide treated with polydimethylsiloxane having terminal trimethylsiloxy groups.

44. (new) The transdermal therapeutic system according to claim 41, wherein said acrylate is selected from the group consisting of:

homopolymers of acrylic acid, copolymers of acrylic acid, terpolymers of acrylic acid, homopolymers of derivatives of acrylic acid, copolymers of derivatives of acrylic acid, and terpolymers of derivatives of acrylic acid.

45. (new) The transdermal therapeutic system according to claim 41, wherein said acrylate is an acrylate polymer of at least one monomer of acrylic acid or a derivative thereof.

46. (new) The transdermal therapeutic system according to claim 45, wherein said acrylate polymer further comprises at least one other copolymerizable monomer.

47. (new) The transdermal therapeutic system according to claim 45, wherein said acrylate polymer further comprises at least one selected from the group consisting of: copolymers of alkyl acrylates, copolymers of alkyl methacrylates, copolymerizable secondary monomers, and and monomers with functional groups.

48. (new) The transdermal therapeutic system according to claim 47, wherein said acrylate polymer comprises at least 50% by weight of an acrylate polymer of a monomer selected from the group consisting of: acrylate, methacrylate, alkyl acrylate, and alkyl methacrylate; from 0 to 20 % by weight of a functional monomer

copolymerizable with the foregoing; and from 0 to 40 % by weight of another monomer.

49. (new) The transdermal therapeutic system according to claim 48, wherein said acrylate monomers are compounds selected from the group consisting of:
acrylic acid, methacrylic acid, butyl acrylate, butyl methacrylate, hexyl acrylate, hexyl methacrylate, isooctyl acrylate, isooctyl methacrylate, 2-ethylhexyl acrylate, 2-ethylhexyl methacrylate, decyl acrylate, decyl methactylate, dodecyl acrylate, dodecyl methactylate, tridecyl acrylate, and tridecyl methacrylate.

50. (new) The transdermal therapeutic system according to claim 48, wherein said copolymerizable functional monomer is selected from the group consisting of: acrylic acid, methacrylic acid, maleic acid, maleic anhydride, hydroxyethyl acrylate, hydroxypropyl acrylate, acrylamide, dimethacrylamide, acrylonitrile, dimethylaminoethyl acrylate, dimethylaminoethyl methacrylate, tert-butylaminoethyl acrylate, tert-butylaminomethyl methacrylate, methoxyethyl acrylate, and methoxyethyl methacrylate.

51. (new) The transdermal therapeutic system according to claim 36, wherein when (i.) is selected in (b.), said system further comprises a gel fromer selected from the group consisting of:
methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, a carboxyvinyl polymer, sodium glyoxylate, carboxymethylcellulose, and mixtures of the above.